EQS-News: DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies (deutsch)
DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies
^
Dynamics Group AG / Schlagwort(e): Studienergebnisse
DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of
Advanced Therapies
23.12.2025 / 14:36 CET/CEST
---------------------------------------------------------------------------
DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of
Advanced Therapies
Landmark Peer-Reviewed Study Demonstrates First-in-Class Percutaneous
Platform for Organ-Isolated Delivery Across Multiple Indications
ZURICH/SCHLIEREN, Switzerland, December 23, 2025 - DiNAQOR, an innovative
health tech group advancing promising early-stage drug development, today
announced the publication of a landmark peer-reviewed study in JACC: Basic
to Translational Science. The study, titled "Next-Generation Percutaneous
Catheter-Based Closed-Loop Perfusion Concept Enables High-Precision Organ
Delivery of Advanced Therapies", describes a first-in-class, fully
percutaneous, catheter-based closed-loop loco-regional perfusion (LRP)
platform that enables highly precise, organ-isolated delivery of advanced
therapies while substantially shielding the systemic circulation from
off-target exposure, addressing one of the most critical challenges in gene
and cell therapy development.
To accelerate clinical translation and commercialization, initially with a
focus on kidney-targeted gene therapy, DiNAQOR has spun out this technology
and its dedicated renal development programs into, DiNATEQ AG, a newly
established company headquartered in Switzerland. DiNATEQ AG will be led by
Dr. Christian Thirion as Chief Executive Officer and Delegate of the Board
of Directors.
A Step-Change in the Delivery of Advanced Therapies
Safe and efficient in vivo delivery remains one of the most significant
barriers to the broad adoption of gene and cell therapies. Systemic
administration of viral vectors, particularly adeno-associated viruses
(AAVs), has been associated with dose-limiting toxicities, immune
activation, and off-target organ exposure, limiting therapeutic index and
commercial scalability.
The closed-loop LRP platform addresses these limitations by enabling
reversible and complete isolation of an organ's circulation, allowing
therapeutic payloads to be delivered locally under tightly controlled
physiologic conditions. In large-animal translational models, the platform
achieved up to a 69,000-fold higher local payload concentration, up to a
75-fold increase in target-organ transduction efficiency compared with
conventional intravenous administration, and a dramatic reduction in
off-target exposure, while preserving organ function and procedural safety.
From Organ-Specific Innovation to a Broad Delivery Platform
While the kidney served as the initial translational use case, the LRP
platform is inherently organ-agnostic. Built on widely established
interventional and perfusion principles, the technology is designed for
adaptation across multiple solid organs, including the heart, lung, and
liver, as well as for compartmentalized delivery to specific anatomical
regions.
The platform is compatible with a broad range of therapeutic modalities,
including gene and cell therapies, gene-editing systems, RNA-based
medicines, biologics, and high-potency pharmacologic agents. By enabling
localized delivery with reduced systemic exposure, LRP has the potential to
unlock new therapeutic windows for modalities previously constrained by
toxicity or delivery limitations.
Independent Mayo Clinic Editorial Endorses Loco-Regional Perfusion (LRP) as
a Breakthrough in Precision Delivery
In an accompanying editorial, Mayo Clinic experts describe LRP as "a
platform that closes the gap between promise and precision in gene
delivery," highlighting its ability to overcome one of the most persistent
limitations in advanced therapeutics: safe, organ-targeted delivery.
Traditional systemic administration of viral vectors and biologics often
results in widespread off-target exposure, immunogenicity, and dose-limiting
toxicity, preventing promising therapies from reaching their full potential.
The editorial characterizes LRP as a "game-changer in the delivery of
advanced therapies," noting that unlike historical isolated perfusion
techniques, LRP is entirely endovascular and minimally invasive. This
approach may enable scalable, outpatient-compatible precision delivery
across multiple organs, including kidney, heart, liver, and lung, with broad
applicability across gene therapy, RNA therapeutics, and regenerative
medicine.
Leadership Perspectives
Professor Maximilian Y. Emmert, M.D., Ph.D., Professor of Cardiothoracic and
Vascular Surgery at Charité - Universitätsmedizin Berlin and lead author of
the study, commented: "Our closed-loop perfusion system represents a
paradigm shift in how advanced therapies can be delivered in vivo. By
temporarily isolating an organ's circulation, we can achieve a level of
precision and control that has not been possible with systemic delivery
approaches. This platform opens new opportunities across multiple
therapeutic areas."
Dr. Johannes Holzmeister, Founder, Chairman and CEO of the DiNAQOR Group,
added: "This publication validates a delivery platform with implications far
beyond a single organ or indication. Precision delivery is the critical
enabler for the next generation of advanced therapies, and our closed-loop
loco-regional perfusion technology establishes a new benchmark for safety,
efficiency, and translational readiness. By spinning out DiNATEQ AG to focus
initially on kidney disease, we are pursuing a disciplined path to clinical
execution, while preserving the broader platform potential for future
indications and partnerships."
Dr. Christian Thirion, Chief Executive Officer and Delegate of the Board of
Directors of DiNATEQ AG, commented: "DiNATEQ has been established to
translate this powerful delivery platform into meaningful clinical impact,
starting with kidney gene therapy and expanding beyond. The ability to
precisely control exposure at the organ level changes the development
equation for many advanced therapies. Our strategy is to advance this
platform rigorously into the clinic, while partnering with pharmaceutical
and biotechnology leaders to extend its application across additional organs
and therapeutic modalities."
Dr. Josef el Andari, Co-Corresponding Author and Chief Scientific Officer at
DiNAQOR, commented: "Independent validation from Mayo Clinic reinforces what
we believe is a pivotal inflection point for advanced therapies. Too many
transformative programs have failed not because the biology was wrong, but
because delivery caused systemic toxicity. As the editorial makes clear,
loco-regional perfusion closes the gap between biological promise and
clinical reality by enabling therapies to act precisely where they are
needed."
A Platform Built for Pharmaceutical Partnerships
For pharmaceutical and biotechnology partners, the LRP platform offers a
differentiated delivery solution that can enhance the therapeutic index of
advanced-therapy assets, enable lower effective doses, mitigate systemic
toxicity risk, and unlock programs previously constrained by delivery or
safety limitations. The platform is designed to integrate seamlessly into
existing clinical infrastructure, supporting efficient clinical translation
and global scalability.
https://www.jacc.org/doi/epdf/10.1016/j.jacbts.2025.101409
https://www.jacc.org/doi/epdf/10.1016/j.jacbts.2025.101436
About DiNAQOR
DiNAQOR AG is a leading biotechnology company that focuses on creating
category-defining platforms and potentially curative therapeutic approaches
in genetic and advanced therapies. Headquartered in Schlieren, Switzerland,
DiNAQOR is pioneering disruptive technologies in precision delivery, vector
innovation and translational development, with the aim of enabling safer,
more effective, organ-targeted treatments.
Operating as a life science company builder, DiNAQOR creates and scales
focused biotechnology companies around differentiated technology platforms.
Its portfolio includes DiNATEQ AG, which is advancing next-generation
precision delivery technologies; DiNAMIQS, an adeno-associated virus (AAV)
manufacturing and development platform that was spun out of DiNAQOR and
subsequently scaled through a majority-stake transaction with Siegfried AG,
establishing a category-defining, end-to-end GMP viral therapeutics
platform; and DiNABIOS, a leading human cell and tissue CDMO supporting
pharmaceutical partners in R&D and translational development. These ventures
underscore DiNAQOR's proven ability to originate, build, and strategically
scale high-impact biotechnology platforms.
About DiNATEQ
DiNATEQ AG is a biotechnology company pioneering precision delivery
technologies for genetic and advanced therapies. Headquartered in Schlieren,
Switzerland, DiNAQOR integrates proprietary delivery platforms, vector
innovation, and translational expertise to enable safer, more effective
therapies for organ-specific diseases. DiNATEQ AG is a dedicated spin-out
from DiNAQOR focused on translating the closed-loop loco-regional perfusion
platform into clinical-stage kidney gene therapy programs, while enabling
broader platform expansion through strategic partnerships. DiNATEQ AG is led
by Dr. Christian Thirion.
These milestones underscore DiNAQOR's ability to identify high-impact
technologies, build dedicated operating companies around them, and realize
value through partnerships and strategic transactions with global industry
leaders. For more information visit www.dinaqor.com.
Publication Details
Title: Next-Generation Percutaneous Catheter-Based Closed-Loop Perfusion
Concept Enables High-Precision Organ Delivery of Advanced Therapies
Journal: JACC: Basic to Translational Science
Authors: Emmert MY et al.
Affiliations: Charité - Universitätsmedizin Berlin, ETH Zurich, DiNAQOR AG,
DiNATEQ AG
Contact
Nicolas Weidmann
Dynamics Group AG
nwe@dynamicsgroup.ch
+41 43 268 27 44
+41 79 372 29 81 Mobil
---------------------------------------------------------------------------
Zusatzmaterial zur Meldung:
Datei:
https://eqs-cockpit.com/c/fncls.ssp?u=b4211898ce095f4167ffa763bb97489a
Dateibeschreibung: Media Release DiNAQR_DINATEQ_2025_Final
---------------------------------------------------------------------------
Ende der Medienmitteilungen
Originalinhalt anzeigen:
https://eqs-news.com/?origin_id=3b66ec5d-dfda-11f0-be29-0694d9af22cf&lang=de
---------------------------------------------------------------------------
2250728 23.12.2025 CET/CEST
°